One-Alpha* (Alfacalcidol)

Alfacalcidol, the active ingredient in One-Alpha*, is a vitamin D analog presented as a oral formulation for oral use. It treats hypocalcemia, renal osteodystrophy, secondary hyperparathyroidism and osteoporosis in patients requiring calcium metabolism regulation.

GNH USA supplies One-Alpha* as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

One-Alpha* is used to manage disorders of calcium and phosphate metabolism that arise from renal or bone disease pathways. - Hypocalcemia: helps restore normal calcium levels in the blood. - Renal osteodystrophy: improves bone mineralization in patients with chronic kidney disease. - Secondary hyperparathyroidism: reduces excess parathyroid hormone production. - Osteoporosis: supports bone density maintenance and reduces fracture risk.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild stomach upset reported in some patients. - Hypercalcemia: elevated blood calcium levels causing fatigue or weakness. - Hyperphosphatemia: increased phosphate levels, potentially leading muscle cramps. - Headache: occasional mild headache. - Gastrointestinal discomfort: abdominal pain or dyspepsia.

Serious or Rare Side Effects: - Nephrolithiasis: kidney stone formation. - Severe hypercalcemia: can cause cardiac arrhythmias. - Hypervitaminosis D: toxicity leading to calcification of soft tissues. - Allergic reactions: rash, itching, or anaphylaxis. - Metabolic bone pain: unexplained bone pain despite therapy.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor relevant laboratory values. - Renal function: assess creatinine clearance before use. - Serum calcium: check baseline and periodically during treatment. - Serum phosphate: monitor to avoid hyperphosphatemia. - Concomitant vitamin D: avoid excessive combined dosing. - Pregnancy and lactation: use only if clearly needed. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Alfacalcidol may interact with several medicines that affect calcium balance or vitamin D metabolism.

Major Interactions (Avoid): - Thiazide diuretics: increase risk of hypercalcemia. - Calcium supplements: additive effect on serum calcium. - Vitamin D analogues: cumulative toxicity risk.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenobarbital): may reduce alfacalcidol effectiveness. - Corticosteroids: can impair vitamin D metabolism. - Bisphosphonates: may alter bone turnover dynamics.